PLpro
Showing 1 - 9 of 9
COVID-19 Trial in United States (SOC + Intravenous Famotidine, SOC + Placebo)
Completed
- COVID-19
- SOC + Intravenous Famotidine
- SOC + Placebo
-
Bay Shore, New York
- +4 more
Dec 10, 2020
COVID Trial (Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2) plus Aerosolized 13 cis retinoic acid)
Not yet recruiting
- COVID
- Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2) plus Aerosolized 13 cis retinoic acid
- (no location specified)
Jun 5, 2021
COVID-19 Trial (Drug: Isotretinoin plus Tamoxifen, Aerosolized Isotretinoin plus Tamoxifen)
Not yet recruiting
- COVID-19
- Drug: Isotretinoin plus Tamoxifen
- Aerosolized Isotretinoin plus Tamoxifen
- (no location specified)
Jul 10, 2021
Covid19 Vaccine Trial (drug, combination product, biological)
Not yet recruiting
- Covid19 Vaccine
- Oral 13 cis retinoic acid
- +4 more
- (no location specified)
May 28, 2021
Covid19 Trial in Cairo (Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) plus Aerosolized Itraconazole, Drug:
Not yet recruiting
- Covid19
- Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) plus Aerosolized Itraconazole
- Drug: Isotretinoin(Aerosolized 13 cis retinoic acid)
-
Cairo, Kafr El-sheikh, EgyptKafr El-sheikh University
Oct 5, 2020
COVID19 Trial in Cairo (Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment, Isotretinoin(Aerosolized 13 cis
Not yet recruiting
- COVID19
- Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment
- +4 more
-
Cairo, Kafr El-sheikh, Egypt
- +1 more
Jul 29, 2021
COVID-19 Trial (Isotretinoin Only Product in Oral Dose Form)
Unknown status
- COVID-19
- Isotretinoin Only Product in Oral Dose Form
- (no location specified)
Sep 20, 2020